Company Interview / LTR Pharma funded with the FDA in its sights

LTR Pharma (ASX: LTP) COO Peter McLennan details how the recent $25 million capital raise will fuel LTR's US expansion, and help bring about commercialisation, along with regulatory engagements with the US FDA and TGA. With the size of the total addresssable market, Peter says LTR Pharma remains focused on manufacturing and distribution strategies in the US market.

On the LTR Pharma product, Peter highlights remarkable results from a clinical study indicating a 470% faster onset rate for a new erectile dysfunction treatment compared to standard options. Peter says the product which bypasses traditional digestion obstacles, provides faster and consistent effectiveness.

Listen for the latest on LTR Pharma's recent telehealth platform partnership, which Peter says continues to gain traction in the marketplace.